menu
    • menu
    [{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Tucidinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Eisai"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Dong-A Socio Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Dong-A Socio Holdings"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Belumosudil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Series B Financing","leadProduct":"OVX836","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Meiji Seika Pharma

    Menu

    Meiji Seika Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Osivax

                            Deal Size : $10.4 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Osivax Gains Strategic Funding for Influenza Vaccine Development

                            Details : The financing aims to fund the clinical development of OVX836, Osivax’s vaccine candidate. It is being evaluated for the treatment of influenza.

                            Product Name : OVX836

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 04, 2025

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Osivax

                            Deal Size : $10.4 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meiji Seika Launches REZUROCK® Tablets in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2024

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meiji Seika Receives Approval for REZUROCK® in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Drug Application for ME3208 Submitted in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 27, 2023

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ME3208 Receives Orphan Drug Designation in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2023

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monoclonal Antibody

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Foundation for Biomedical Research and Innovation at Kobe

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research Between Mei...

                            Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 16, 2023

                            Lead Product(s) : Monoclonal Antibody

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Foundation for Biomedical Research and Innovation at Kobe

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ME3183

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis...

                            Details : In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor ...

                            Product Name : ME3183

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2022

                            Lead Product(s) : ME3183

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ME3183

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Tr...

                            Details : ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.

                            Product Name : ME3183

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2021

                            Lead Product(s) : ME3183

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115

                            Details : Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.

                            Product Name : DMB-3115

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 21, 2021

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Dong-A Socio Holdings

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115

                            Details : A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.

                            Product Name : DMB-3115

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 21, 2021

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Dong-A Socio Holdings

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth